2/2
08:00 am
apm
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
High
Report
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
12/17
04:32 pm
apm
Aptorum Group (NASDAQ:APM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aptorum Group (NASDAQ:APM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/5
04:14 pm
apm
Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/29
03:34 pm
apm
Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:11 am
apm
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference [Yahoo! Finance]
Low
Report
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference [Yahoo! Finance]
11/19
08:00 am
apm
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
Low
Report
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference